Phenobarbitone |
1. 30 mg p.o. |
30–60 mg p.o. every 3 days (long half-life) (∼60–180 mg/day) |
Fatigue, pronounced cognitive decline, headaches, ataxia, nystagmus, depression, agitation, aggression, hyperkinesia (children), megaloblastic anaemia,teratogenicity, vitamin K deficiency in new-borns; rapid titration in status: respiratory depression |
Oral, i.v., s.c., i.m. |
2. (rapid) 50 mg i.v., s.c. or i.m. every 6 hours diluted 1∶10 with inj. water |
3. (status) 20 mg/kg i.v. diluted 1∶10 with inj. water (start with 200–400 mg) (maximum rate: 100 mg/minute) |
Carbamazepine |
200 mg p.o. |
200 mg p.o. every 3 days (∼800–2000 mg/day) |
Vertigo, double vision, nystagmus, ataxia, movement disorders, hyponatraemia, leucopenia, rash, nausea, fatigue, liver failure, teratogenicity |
Oral |
Phenytoin |
1. 300 mg p.o. |
25–50 mg p.o. per day (∼200–500 mg/day) |
Vertigo, double vision, nystagmus, tremor, movement disorders, rash, megaloblastic anaemia, leuco-, thrombopenia, fatigue, acne, osteopathy, gingival hyperplasia, liver failure, irreversible cerebellar atrophy, teratogenicity; rapid titration in status: cardiac dysrhythmias, hypotonia |
Oral, i.v. (beware of phlebitis) |
2. (rapid) 600 mg p.o. for 3 days |
3. (status) 1.5 g i.v. diluted 1∶10 with inj. water (first 250 mg as bolus, next 500 mg in 0.5 to 6 hours, next 750 mg in 1–24 hours according to clinic) (maximum rate: 20 mg/minute) |